Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.
Luz M MedranoNorma RallónJuan BerenguerMaría A Jiménez-SousaVicente SorianoTeresa Aldámiz-EchevarriaAmanda Fernández-RodríguezMarcial GarcíaFrancisco TejerinaIsidoro MartínezJosé M BenitoSalvador Resino GarcíaPublished in: Journal of translational medicine (2016)
TRIM5 and TRIM22 SNPs are associated to increased odds of significant liver fibrosis and SVR after pegIFNα/RBV therapy in HIV/HCV coinfected patients. Besides, TRIM5 SNP was associated to higher baseline levels of circulating biomarkers GRO and MCP-1.
Keyphrases
- hepatitis c virus
- end stage renal disease
- human immunodeficiency virus
- ejection fraction
- newly diagnosed
- chronic kidney disease
- liver fibrosis
- antiretroviral therapy
- hiv infected
- hiv positive
- peritoneal dialysis
- prognostic factors
- genome wide
- hiv testing
- patient reported outcomes
- men who have sex with men
- cell therapy
- smoking cessation